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Introduction
The previous issue of the Journal of Hematopathology
lacked a review of the literature because there were five
commentaries on the 2008 classification by members of the
editorial team [1–5] and the first regular review on literature
for bone marrow pathology by Jon VanderWalt [6].
Therefore, this issue contains a quite long review of the
literature covering the first half of 2009, a longer period
compared to the previous three reviews [7–9] and the
selection was therefore, more strict.
The wealth of information that is coming available is
more and more difficult to grasp, and reviews like this can
only lift a tip of the veil. Huang et al. [10] have developed
an intelligent database that enables to integrate many data
that are available on lymphoma patients. Since the majority
of patients are not the average patient, this type of approach
may be helpful to reach a level of knowledge that will
enable real personalized medicine, by comparing many data
of an individual patients to those present in the database. In
principle, the opposite approach to collecting large amounts
of data and comparing that to individual patients is to try to
unravel the pathogenesis of lymphomas by experimental
work. Also in the last months, exiting new data have
become available which will eventually lead to more
biological approaches in the treatment of lymphoma
patients.
Blocking the effect of gene activation by mRNA
interference is a promising approach for various tumor
types. It is therefore quite helpful that Anastasov et al. [11]
were able to develop an efficient lentiviral vector-based
system to study gene knockdown in lymphoid cell lines.
The work will form the foundation of a series of studies on
the effect of knocking out specific proteins in cell cultures.
Biology of lymphoma
Hodgkin lymphoma
Now that a large amount of biological features of Hodgkin
lymphoma (HL) tumor cells has become available, amongst
others, by studying cell lines, several new drugs are being
tested preclinically. Hartlapp et al. [12] show that targeting
multiple signaling pathways by inhibition of histone
deacetylase using depsipeptide results in apoptosis induc-
tion and cell cycle inhibition. Especially the inhibition of
apoptsis had been difficult to achieve so far, and thus, this
might be a promising new treatment for HL patients.
It is now well-known that HL represents a B cell
neoplasia with an aberrant B cell differentiation program.
Jones et al. [13] pursue an already old observation that in
the culture of HL cell lines small populations of phenotypic
normal B cells occur that express immunoglobulin. They
were able to demonstrate that this small population is the
precursor and generator of the HL cells, and also that such
cell can be found in the blood of HL patients, regardless of
stage.
B cell lymphomas
As referred to in the previous review [9], the tumor
microenvironment was the main topic at the European
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but that our understanding is far from complete. Maby-El
Haijami et al. [14] show that resting human mesenchymal
stem cells (MSC) sustain activated normal B cell prolifer-
ation and survival, whereas IFN-gamma-conditioned MSCs
mediate B cell growth arrest and apoptosis. IFN-gamma,
TNF, and lymphotoxin-alpha1beta2 (LT) are significantly
overexpressed by the microenvironment of follicular lym-
phoma (FL), but their relative expression patterns are
highly heterogeneous between samples. In vitro, IFN-
gamma abrogates the B cell supportive phenotype induced
by TNF and LT on MSCs. Moreover, IFN-gamma overrules
the growth promoting effect of MSCs on primary purified
FL B cells. Altogether, these results underline the crucial
role of the cytokine context in the local crosstalk between
malignant cells and their microenvironment and provide
new insights into our knowledge of the FL cell niche that
emerges as a new promising target for innovative thera-
peutic strategies. But cytokines have not only an effect on
MSCs. Especially in FL it is well-known that T cells are an
important component of the microenvironment. Yang et al.
[15] show that in B cell lymphoma samples the amount
TH17 cells is decreased and by using cell cultures they
showed that this is due to IL-2 production by malignant B
cells, that activates regulatory T cells, which in turn
downregulates the number of TH17 cells. In mantle cell
lymphoma (MCL), Kurtova et al. [16] found high levels of
CXCR4, CXCR5, and VLA-4. Since these chemokine
receptors and adhesion molecule enable cell motility and
migration, this finding may explain the often early high
stage of disease patients present with.
The relation between B and Tcells was even more intimate
in observations by Krejsgaard et al. [17]. It was already
known that B-lymphoid kinase (Blk), normally expressed in
B cells and thymocytes only, transferred into mature T cells
results in T cell lymphomas. They observed that Blk can be
found in cutaneous T cell lymphomas, but not in benign T
cell infiltrates, a finding when confirmed is quite relevant.
Anti CD20 antibodies are now a cornerstone in the
therapy of B cell lymphomas. Rossi et al. [18] developed
bispecific antibodies, anti CD20/CD22, and showed that in
vitro these lead to apoptosis of B cells, and more efficiently
in B cell lymphoma cells.
The relation between specific infections and extranodal
marginal zone lymphomas (MZL) is well-known, with H.
Pylori (HP) activating specific anti-HP T cells driving the
lymphoma cells as prime example. The mechanism may be
different in ocular marginal zone lymphomas since Bahler
et al. [19] show that these lymphomas use specific
immunoglobulin VH gene segments. Furthermore, the
mutation spectrum suggests antigen-driven selection, and
thus a potential antigen may have a more direct effect on
the tumor cells in these cases.
Novak et al. [20] were able to demonstrate another
common feature in MZL of various sites. Homozygous
deletions of the chromosomal band 6q23, involving the
tumor necrosis factor alpha-induced protein 3 (TNFAIP3,
A20) gene, a negative regulator of NF-kappa B, had already
been described in ocular adnexal MZL. Inactivating
mutations encoding truncated A20 proteins were present
in six (19%) of 32 MZLs, including two (18%) of 11
extranodal MZLs, three (33%) of nine nodal MZLs, and
one (8%) of 12 Splenic MZLs. Two additional unmutated
nonsplenic MZLs also showed monoallelic or biallelic A20
deletions by fluorescent in situ hybridization (FISH) and/or
SNP-arrays. Thus, A20 inactivation by either somatic
mutation and/or deletion represents a common genetic
aberration across all MZL subtypes. These findings are to
be taken with care, since many other features clearly
distinguish SMZL from the other two types.
Mantle cell lymphoma is a very widely studied tumor
type, and may have a highly complex karyotype next to the
characteristic t (11; 14). Wang et al. [21] show that MCL
have high levels of Jun kinases (JNK) mitogen-activated
protein kinase, and that this is needed for cell proliferation
and maintaining diploidy. In a subset of MCL’s, loss of
JNK results in a hyperdiploid state.
Now that technology to study genome-wide methylation
hasbecomeavailable,itisnosurprisethatalsolymphomasare
studied using this powerful method. Bennett et al. [22]
analyzed FL and compared the results to benign lymph
follicles. The results indicate that extensive hypermethylation
in promoters of polycomb target genes is a characteristic of
FL, and that loss of expression of certain SUZ12 target genes
could be functionally relevant for lymphomagenesis. Using a
more traditional approach, Kondo et al. [23] found that
gastric lymphomas, both MZL and diffuse large B cell
lymphomas (DLBL), have many hypermethylated CGP
islands, and that in gastric specimens without lymphoma,
only hypermethylation was seen in case of HP infection.
This suggests that hypermethylation may be an early event in
EMZL lymphomas under the influence of HP infection.
Interleukin (IL)-21 has been recently shown to modulate
the growth of specific types of B cell neoplasm, and MCL
expresses the IL21 receptor. Gelebart et al. [24] show that
IL-21 can effectively induce apoptosis in MCL via a
STAT1-dependent pathway, which may be useful in
designing novel therapeutic approaches.
Although the frequent occurrence of bcl-6 abberations in
DLBL is well-known, the functional consequences were
enigmatic. In a series of elegant experiments, Saito et al.
[25] show a link between bcl-6 and bcl-2 in DLBL
explaining the mutual exclusive gene alteration of bcl-2
and bcl-6. In normal germinal center B cells, BCL6 binds to
the BCL2 promoter region by interacting with the tran-
scriptional activator Miz1 and suppresses Miz1-induced
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sion of BCL2 is lost in FL and DLBCL, where the two
proteins are pathologically coexpressed, because of BCL2
chromosomal translocations and other mechanisms, includ-
ing Miz1 deregulation and somatic mutations in the BCL2
promoter region. These results identify an important
function for BCL6 in facilitating apoptosis of germinal
centre (GC) B cells via suppression of BCL2, and suggest
that blocking this pathway is critical for lymphomagenesis.
Although the association between Burkitt lymphoma
(BL) and Epstein–Barr virus (EBV) infection is well-
known, the exact mechanism by with the virus results in
lymphoma development is not clear: in BL-cells, EBV is
not always present. It has been suggested that EBV-positive
and EBV-negative BL have different cells of origin. In
particular, according to immunoglobulin gene mutation
analysis, EBV-negative BLs may originate from early
centroblasts, whereas EBV-positive BLs appears to arise
from postgerminal center B cells or memory B cells. Leucci
et al. [26] found that hsa-miR-127 is differentially
expressed between EBV-positive and EBV-negative BLs.
In particular, it was strongly upregulated only in
EBV-positive BL samples, whereas EBV-negative cases
showed levels of expression similar to normal controls,
including microdissected GC cells. In addition, they found
evidencethathsa-miR-127isinvolvedinBcelldifferentiation
process through post transcriptional regulation of BLIMP1
and XBP1. The overexpression of this mRNA may thus
represent a key event in the lymphomagenesis of EBV
positive BL, by blocking the B cell differentiation process.
The Janus kinase 2 (JAK2)-signal transducers and
activators of transcription pathway plays an important role
in hematological malignancies. Mutations and transloca-
tions of the JAK2 gene, mapped at 9p24, lead to
constitutive activation of JAK2 and its downstream targets.
The presence of JAK2 mutations in lymphomas has been
addressed in larger cohorts, but there are little systemic data
on numerical and structural JAK2 aberrations in lymphoid
neoplasms. Using TMAs and FISH with split signal JAK 2
probes, Meier et al. [27] show that 9p24 gains were present
in six of 17 (35%) primary mediastinal B cell lymphomas,
25 of 77 (33%) Hodgkin's lymphomas, three of 16 (19%)
angioimmunoblastic T cell lymphomas, and one of five
ALK1 (+) anaplastic large cell lymphomas; breaks were
observed only in three cases. They stress that despite the
rarity of activating JAK2 mutations in lymphomas, JAK2 is
recurrently targeted by numerical, and rarely by structural,
genetic aberrations in distinct lymphoma subtypes.
T cell lymphoma
The mechanism causing chromosomal translocations
involving antigen receptors are quite well understood, but
much more limited ideas exist on other translocations.
Mathas et al. [28] investigated anaplastic large cell
lymphoma (ALCL) cases with and without a t (2; 5)
translocation and found that that several genes near both
breakpoints are dysregulated regardless of whether the
translocation is present. The authors speculate that the
activity of these genes may be related to the occurrence of
the translocation itself, thereby assuming the both types
of ALCL represent the same entity.
Also, Lim et al. [29] show that many more genes than
those involved in the translocation are aberrantly expressed
in ALCL. Using mass spectrometry, they identified protein
expression signatures related to, amongst others, cell survival
and angiogenesis. They also found that a subset of proteins
distinguished ALK-positive from ALK-negative cases.
Singh et al. [30] focused on the sonic hedgehog
signaling (SHH) pathway, and demonstrate that this
pathway is activated in ALK-positive ALCL due to SHH
gene amplification and is further mediated by NPM-ALK
through activation of PI3K/AKT and stabilization of GLI1
protein. Dien Bard et al. [31] look into the JAK3/STA3
activation which is known to be present in ALK-positive
ALCL using cell lines and tumor samples, and shows that
next to other factors, IL-21 contributes to that activation.
Finally, although overexpressed at the RNA level, Bobos et
al. [32] could not detect overexpression of cyclinD1 at the
protein level in ALCL. All this work indicates the
complexity of tumorigenesis in lymphomas, even in a type
that has such a characteristic translocation as Alk-positive
ALCL.
Epidemiology of lymphoma
Etiological studies into lymphomas are difficult, due to the
rarity of the different types of lymphoma. The role of the
Epstein–Barr virus is well-established, especially in indi-
viduals with a reduced T cell function. The polyomavirus
SV40 has been detected with various incidences and its role
is not so clear. Toracchio et al. [33] investigated lymphoma
tissue for the presence of these two viruses. They show that
in Houston, there exist a difference in frequency of the
polyomavirus and EBV, with 23% and 39% in one hospital
and 3% and 18% in another, whereas the lymphoma type
distribution was similar. The polyomavirus occurred more
often in younger patients and in T cell lymphomas. These
results show that marked differences in involvement of
viruses occur even in areas from the same city. Another
virus that is involved in the pathogenesis of some
lymphomas is the Human herpesvirus 8 (HHV8), especially
in patients with HIV. According to a study by Chen et al.,
[34] on 52 posttransplant lymphoproliferative disorders,
HHV8 does not play a role in this entity.
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mised patients and that germline polymorphisms are well-
known for solid cancers, it does not come as a surprise that
such polymorphisms are relevant in lymphoma develop-
ment too. Morton et al. [35] studied almost 2000 patients
and controls for the presence of single nucleotide poly-
morphisms (SNP’s) in 203 genes and found significant
differences between patients with specific lymphoma types
and controls. They indicate that the results support the role
of genetic variation in cell cycle, apoptosis, and lymphocyte
development regulatory genes in lymphomagenesis, and
suggest that effects may vary by nonhodgkin lymphoma
(NHL) subtype.
Geographical variation in incidence of lymphoma types
is well-known. In most cases, the cause of this variation is
not clear. An important point to understand this variation
lies in case definition and molecular findings. A Chinese
series of chronic lymphocytic leukemia (CLL) was molec-
ularly characterized revealing some remarkable differences.
In China, CLL is rare and the most frequent cytogenic
findings were the occurrence of 14q breaks in 24% of the
cases (Irons et al. [36]). The mutation status was prognos-
tically significant, like in Western series, but in contrast,
trisomy 12 was not.
Defining entities
Hodgkin lymphoma
The diagnosis of lymphocyte rich classical HL (cHL) can
be difficult. Nam-Cha et al. [37] compared this type of HL
with the other types of cHL and with nodular lymphocyte
predominant (NLP)-HL. Lymphocyte-rich cHL displayed
features intermediate between those of cHL and NLP-HL.
The expression of B cell transcription factors such as Oct.1,
Oct.2, Bob.1, and BCL6 was more frequent in lymphocyte-
rich cHL than in cHL. A follicular T cell microenvironment
was also identified in 50% of lymphocyte-rich classical
Hodgkin's lymphoma cases. NF-kB markers were
expressed at frequencies comparable with those observed
in cHL. Lymphocyte-rich cHL was characterized by a
stronger expression of the B cell transcription program by
the neoplastic cells and by a follicular T cell background,
occupying an intermediate position between cHL and
NLP-HL. According to a study of Bharqava et al. [38]o n
35 archival cases of NLP-HL (n=24) and LRcHL (n=11)
from adults and children, fascin and junB expressions can
be used as markers to separate these subtypes: Whereas,
occasional L and H cells were weakly positive for fascin in
three out of 24 (12.5%) cases of NLP-HL, RS cells in
LRCHL were positive for fascin in 11 out of 11 (100%)
cases with a strong cytoplasmic staining pattern. JunB was
positive in ten out of 24 (41.7%) of NLP-HL cases, and 11
out of 11 (100%) of LRCHL cases, showing a stippled
and/or diffuse nuclear staining pattern. The L and H cells of
NLP-HL cases were negative for concomitant staining in 24
out of 24 (100%) cases. Concomitant positive staining of
classic RS cells for fascin and JunB was found in 11 out of
11 (100%) of LRCHL cases.
Lymphocyte depleted (LD) HL had been a bit neglected
the last years, but regained interest lately (see previous
review; 9). Slack et al. [39] studied eight cases that fulfilled
diagnostic criteria of LDHL according to the 2008 World
Health Organization classification. The cases involved
lymph nodes (seven cases) and pleura (one case) from four
males and four females (age 30–71 years; median 62 years).
All tumors contained numerous Hodgkin–Reed Sternberg
(HRS) cells, fibroblasts and histiocytes, and scattered
lymphocytes. In three cases, the tumors had a more diffuse
fibrotic appearance, while in five cases they appeared
reticular and anaplastic. Neoplastic cells in all cases
expressed CD30, CD15, fascin, weak PAX5, and MUM-1
and lacked CD45, Alk-1, EMA, CD3, CD68, Mart-1, and
cytokeratin. Oct.2 and/or Bob-1 were expressed in all cases.
Two cases variably expressed CD20 but were CD79a
negative. Four cases were positive for EBV. All the four
cases with adequate DNA had clonally rearranged IGH
genes. The combined morphologic, immunophenotypic
and molecular genetics features of this group of cases
distinguish LDHL from other disease entities, including
gray-zone lymphomas.
B cell lymphomas
Precursor B-lymphoblastic leukemia/lymphoma is accord-
ing to the WHO-classification one entity, although the
clinical presentation of the lymphoma cases differs mark-
edly from the leukemic ones. Schaders et al. [40] used
genomic profiling and found that there are subtle but
significant differences between the two types of presenta-
tion, whereas that was not the case for T-lymphoblastic
lymphoma/leukemia. Whether or not this indicates that this
points to a different pathogenesis remains unclear.
After it became clear in the late eighties of the previous
century, mainly through work of Peter Isaacson, that nodal
and extranodal lymphomas are different, many studies into
lymphomas of specific sites have been published.
Schniederjan et al. [41] describe 40 lymphomas from the
urinary tract and genital organs (but not testis and ovary).
This study confirms the predominance of diffuse large B
cell lymphoma in extranodal sites, the findings also
highlight the variety of lymphomas that may occur in the
genitourinary tract; only four cases of marginal zone
lymphoma were seen, all in the kidney, none in the bladder.
This diversity of subtypes affirms the importance of fully
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other modalities. Validire et al. [42] describe 45 lymphomas
with breast incolvement, 38 of which were DLBL. Most
cases had lymph node involvement and thus were not
primary breast lymphomas. The survival data confirm that
nodal lymphomas that present with extranodal involvement
have a poorer outcome. Mozos et al. [43] describe a series
of ten cases of the rare primary adrenal lymphoma.
Histologically, eight cases were DLBL, all of which carried
a nongerminal center B cell phenotype. Fluorescence in situ
hybridization revealed BCL6 gene rearrangement in five
(83%) of six DLBL investigated. The prognosis of these
patients was poor as compared with those with nodal
DLBL. The remaining cases were one case each of
plasmablastic lymphoma and extranodal NK/T cell lym-
phoma, nasal type, the first and third case of primary
adrenal lymphoma of these particular lymphoma subtypes
in the English literature, respectively.
Yin et al. [44] describe six new cases of CLL with
t (2; 14), involving the Bcl11A gene. This series differs
from other cases of CLL since they have irregular nuclei
and plasmacytoid differentiation and all were unmutated.
CD103 is a good marker for hairy cell leukemia
(HCL), but other lymphoproliferations with CD103
expression exist. Dong et al. [45] describe 215(!)
CD103-positive lymphoproliferations. Almost 80% coex-
p r e s s e dC D 2 5i n d i c a t i v eo fH C L ,a l lo fw h i c hw e r e
annexin-A1 positive. All cases negative for annexin-A1
lacked CD25 also. The remaining 20% of cases had a
variable morphology and phenotype representing HCL
variant, splenic marginal zone lymphoma, prolymphocytic
leukemia, and DLBL and did not respond to stand HCL
therapy. It is actually curious that such treatment had been
g i v e nt ot h o s ep a t i e n t s .
Ongoing studies of the Kluin-group in Groningen into
testicular and central nervous lymphomas (so called
immune-privileged sites) have shown several specific
features of this group of DLBL. In a study on the
expression of 15 microRNAs (miRNAs) of 50 DLBL
(19 localized nodal, 11 testicular, nine CNS, and 11 other
extranodal ones) they show that MiR-17-5p has higher
expression level in the CNS cases compared to testicular
and nodal DLBL. MiR-127 levels were higher in testicular
than in central nervous system and in nodal DLBL. They
conclude that the site of presentation of DLBL is an
important factor in determining the differential expression
of miRNAs (Robertus et al. [46]).
For CLL, the mutation status of the immunoglobulin
gene is an important prognostic factor, but for MCL this is
not so clear. Schraders et al. [47] show, using many clinical
and pathological features, including CGH and expression
array, that mutation status in this disease does not indicate a
clinical and biological subentity.
Translocation t (11; 18; q21; q21) is the most frequent
chromosomal aberration reported in gastric mucosa-
associated lymphoid tissue lymphomas. Intriguingly, this
translocation has been reported only rarely in diffuse large
B cell lymphomas; it has been proposed that t (11; 18)-
positive tumors rarely progress to diffuse large B cell
lymphomas. Torrachio et al. [48] investigated the occur-
rence of this translocation in primary gastric lymphomas,
both MZL and DLBL. Remarkably, the frequency was
similar in both groups, about 20–25%. It is an intriguing
question whether this might also indicate response to HP
eradication in the BLBL cases.
Nodal marginal zone lymphoma (NMZL) is difficult to
diagnose, since there is not a specific phenotype.
Especially the differentiation from FL is sometimes
difficult. Kanellis et al. [49] selected from expression array
data myeloid cell nuclear differentiation antigen (MNDA),
a nuclear protein expressed by myeloid cells and a subset of
B cells. MNDA was expressed in subgroups of CLL, MCL,
and DLBL, but MNDA was especially expressed by
lymphomas derived from the marginal zone, such as
mucosa-associated lymphoid-tissue lymphoma, splenic
MZL, and NMZL. MNDA expression was rarely observed
in FL, a characteristic that is of potential value in
distinguishing NMZL from FL.
The t (14; 18) is the hallmark of FL, but various
frequencies of negative cases are described, depending on
the technique used to detect the translocation. A series of 17
t (14; 18) negative FL was studied by Leich et al. [50], and
they found that in contrast to positive cases, no numerical
aberrations in the bcl2 region and in addition a different
gene expression profile. Remarkably, the cases were weak
or negative for CD10, which opens the question whether
cases might represent nodal marginal zone lymphomas with
completely colonized germinal centers. A remarkably large
series of t (14;1 8) negative FL (63 out of 142 cases of FL)
was investigated by Gu et al. [51] using FISH and show
that there is a similar frequency of bcl6 breaks compared to
t (14; 18) positive cases, but that the breakpoint differs.
Two studies on FL of the spleen were done. Howard et
al. [52] describe 16 cases, all with bcl2 or bcl6 breaks,
positive for bcl2 and CD10, but often pure intrafollicular
growth, which makes the differential diagnosis with
reactive lesions difficult. Spleen weight remains an impor-
tant issue! A series of 32 cases by Mollejo et al. [53] had
different results: 20 had weak or absent bcl2 staining and
many of these were CD10 negative and lacked a break in
bcl2. This latter group had a higher proliferation rate and
was more often restricted to the spleen. It is likely that such
cases have been given another diagnosis, i.e., marginal zone
lymphoma, by Howard et al. [52]
Chromosomal breaks in the MYC gene are characteristic
for Burkitt lymphoma but occur also in progressed
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clinical course and it is debated whether morphological
features point towards cases with potential MYC break.
Obermann et al. [54] studied 333 DLBL with FISH for
MYC, and had a reliable result in 220 of these. Only nine
(4%) had a MYC break but these could not be predicted
using conventional methods, including proliferative index.
The authors suggest that routine screening of DLBL for
MYC break is needed, but with such a low percentage, a
cost-effectiveness study is called for. In BL, MYC breaks
are not the only genomic change and Molina-Privado et al.
[55] provided evidence based on studies in cell lines and
tumor samples that E2F1 is also overexpressed in almost all
sporadic BL.
Korac et al. [56] investigated the expression of FoxP1 in
multiple myeloma and monoclonal gammopathy of unde-
termined significance and show that there is expression in
contrast to normal plasma cells, and also that there is an
increased gene copy number.
T cell lymphomas
In celiac disease patients, abnormal T-lymphocytes may
occur intraepithelial in the small bowel. Using flow
cytometry Verbeek et al. [57] analyzed the T-lymphocytes
in celiac disease patients with aberrant T cells in the lamina
propria and in skin lesions, and found that also in these
compartments, aberrant cells can be found.
Cho et al. [58] reiterate the difficulties that may occur in
evaluating staging bone marrow biopsies from patients with
angioimmunoblastic T cell lymphoma (AILDT). In a series
of 33 patients, about 70% had a positive marrow, but about
one-third had been missed initially. Especially when clinical
data are lacking cases with a mixed infiltrate were not
recognized.
Rarely, T cell lymphomas have a follicular growth
pattern, and such cases are suggested to be associated with
t (5; 9). Huang et al. [59] studies 30 such cases and that
these are often CD4, CD10, Bcl6, PD-1, CXCL13, and
ICOS positive, a pattern that is similar to that of follicular
helper T cells; four of 22 had the translocation. Three
patients had in-follow biopsies AILDT.
Falchook et al. [60] describe their experience with 15
patients who had gamma-delta T cell lymphoma and
confirmed the poor outlook in this disease: Median overall
survival was 11 months (range 2 to 36+ months)
Most cases of T cell large granular lymphocytosis carry
the alpha beta T cell receptor, but occasional cases have
gamma delta receptors. Shaw et al. [61] describe two such
cases which appeared in most clinical and pathological
features very similar to the common type.
Although it is well known that CD99 is not specific for a
certain disease, it is remarkable that 103 out of 160 ALCL
stain for this antibody. In contrast to the suggestion of
Buxton et al. [62], this antibody was not initially described
as a marker for Ewings sarcoma, but for precursor T cells.
The tumor cells in ALCL are, however, mature T cells.
A very large series of 136 cases of primary CD4 positive
cutaneous T cell lymphoma was described by Beltraminelli
et al. [63]. Patients with skin nodules characterized by the
infiltrate of pleomorphic small/medium T lymphocytes are
currently classified as “primary cutaneous CD4+ small-/
medium-sized pleomorphic T cell lymphoma” or as T cell
pseudolymphoma. The distinction is often arbitrary, and
patients with similar clinicopathologic features have been
included in both groups. All but three patients presented
with solitary nodules located mostly on the head and neck
area (75%). Histopathologic features were characterized by
nonepidermotropic, nodular, or diffuse infiltrates of small-
to medium-sized pleomorphic T lymphocytes. A monoclo-
nal rearrangement of the T cell receptor-gamma gene was
found in 60% of tested cases. Follow-up data available for
45 patients revealed that 41 of them were alive without
lymphoma after a median time of 63 months (range:
1–357 months), whereas, four were alive with cutaneous
disease (range: 2–16 months). The incongruity between the
indolent clinical course and the worrying histopathologic
and molecular features poses difficulties in classifying
these cases unambiguously as benign or malignant, and it
may be better to refer to them with a descriptive term
such as “cutaneous nodular proliferation of pleomorphic
T lymphocytes of undetermined significance,” rather than
forcing them into one or the other category.
New entities/subtypes
The data on IgG4 disease are accumulating fast. Sato et al.
[64] compare IgG4-related lymphadenopathy (nine cases)
with multicentric Castleman’s disease. Histologically, sys-
temic IgG4-related lymphadenopathy was classified into
two types by the infiltration pattern of IgG4-positive cells:
interfollicular plasmacytosis type and intragerminal center
plasmacytosis type. The interfollicular plasmacytosis type
showed either Castleman's disease-like features or atypical
lymphoplasmacytic and immunoblastic proliferation-like
features. By contrast, the intragerminal center plasmacyto-
sis type showed marked follicular hyperplasia, and infiltra-
tion of IgG4-positive cells mainly into the germinal centers,
and some cases exhibited features of progressively trans-
formed germinal centers. Since eight of the nine cases had
eosinophil infiltration in the affected tissue and elevation of
serum IgE, the authors suggest an allergic mechanism in the
pathogenesis of systemic IgG4-related lymphadenopathy.
Chen et al. [65] describe five B cell neoplasias with
CDK6 translocation. Common clinical characteristics
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lymphadenopathy, splenomegaly, and bone marrow
involvement. Three patients were diagnosed with low-
grade B cell lymphoma and had an indolent clinical course,
and two patients (one who transformed to large B cell
lymphoma, and the other who was initially diagnosed with
a high-grade B cell lymphoma) had an aggressive clinical
course. Immunophenotypically, the neoplastic B cells
expressed CD5, CDK6, and cytoplasmic retinoblastoma 1
protein in all cases, expressed phospho-RB, p27kip1, and
cyclin D2 in most cases, and uniformly lacked expression
of all other cyclins. In four cases, the CDK6 translocation
partner was kappa immunoglobulin light-chain gene; and in
the fifth case, the CDK6 translocation partner was
unknown. These distinct clinicopathologic and cytogenetic
features distinguish the CDK6 translocation-associated
BLPDs from other mature B cell lymphomas.
EBV-positive lymphomas of the elderly have received
quite some attention recently. Gibson et al. [66] collected
six such cases in the US, where this disease seems rare.
They also screened 60 cases of DLBL, in which no case
was EBER positive. The six cases were similar as described
by the Japanese, and also as posttransplant cases.
Maeshima et al. [67] screened 529 cases of DLBL and
found 38 (7.2%) cases positive for CD5. Five cases gained
CD5 expression during the clinical course of DLBCL.
Three cases showed transformation from CD5- low-grade B
cell lymphoma to CD5+ DLBCL. The remaining case
showed coexistence of CD5+ DLBCL and CD5+ follicular
lymphoma. The clonal relationships of CD5- and CD5+
tumors were confirmed in all four available cases. These
results indicate that cases in the east differ from those in the
west, since no MCL were in this group, and CD5 is seldom
seen in Western cases.
Although methotrexate-associated lymphoproliferations
receive less attention in the last WHO classification, it
remains an important topic. Such cases need withdrawal of
the drug rather than chemotherapy, but can only be
recognized when the information on the fact that the patient
uses methotrexate is available to the pathologist. Cases look
very much like regular DLBL or HL or AILT according
Hatanaka et al. [68], based on three cases.
Prognostic factors in lymphoma
Again, the largest number of articles referred this time deal
with prognostic factors. As I discussed in the previous
review [9], the issue now is to have predictive factors. In
this period, an important paper was published that comes up
with a predictive factor. It is widely accepted that at least
two groups of DLBL exists, the activated and germinal
centre type, and that these are prognostically different.
Dunleavy et al. [69] show that bortezomib enhances the
effect of chemotherapy in patients with activated B cell like
DLBL and not in the germinal center type. This makes the
subclassification, for which still no reliable immunohisto-
chemical approach exists, quite relevant. A next step will be
a clinical trial that takes this information into account.
Another study that preludes on a predictive approach
investigates the expression of CD52 in T cell lymphomas,
since ant-CD52 antibodies become available. Jiang et al.
[70] determined by flow cytometry in 78 T cell neoplasias
the level of CD52 expression. All AITL, hepatosplenic-
TCL and T-PLL cases were CD52-positive but CD52
expression was low in ALCL (50%) and ENT/NKCL
(25%). Although the authors suggest that this finding may
be important for treatment selection, clinical data are
needed to determine the minimum level of expression that
warrants treatment with the anti CD52 antibody.
Troncone et al. [71] had shown that high UbcH10
expression indicates aggressive behavior in solid tumors and
now studied this enzyme in lymphomas, both on cell lines and
tissue samples of a variety of types. They show that UbcH10
expression is related to proliferation and that high expression
is found in aggressive lymphomas, the highest in BL.
Marquard et al. [72] studied the expression levels of a
series of proteins of histone deacetylase system, which is
targeted by several new drugs. The shows that HDAC1,
HDAC2, HDAC6, and acetylated H4 are overexpressed in
DLBCL and PTCL relative to normal lymphoid tissue.
Furthermore, HDAC6 indicated favorable outcome in
DLBCL and a more aggressive course in PTCL.
Diepstra et al. [73] studied a large series of 412
patients with classical HL for the clinical relevance of
EBV-infection. About one-third was positive and these
had a better 5 years survival, but only in the age group
from 50–74 years. In this age, group EBV negative cases
had a 5 years survival of only 60% versus 85%.
Retuximab is now a cornerstone in the treatment of B
cell lymphomas. Johnson et al. [74] show that mutation in
this gene are rare and not prognostically relevant in B cell
lymphomas at diagnosis and relapse, so mutation analysis
of the CD20 gene has no role in routine practice.
It is quite clear that the future of array studies leis in the
use of formalin-fixed and paraffin-embedded tissues.
Sanchez-Espiridion et al. [75] studied such tissues from
52 cases of HL with a low-density array and were able to
successfully use more than 80% of the samples and develop
a predictor for relapse free survival. A more standard
approach was taken by Canioni et al. [76] who studied 59
cases with immunohistochemistry: expression of bcl2 and
CD20 in Hodgkin and Reed Sternberg cells, and expression
of TiA1 in microenvironmental lymphocytes, and c-kit
positive mast cells in microenvironment, were independent
prognostic markers.
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approach in FL where they analyzed the growth pattern in
457 patients in relation to survival. Since they found no
independent value of this factor, reporting the amount of
follicular growth is not necessary. In contrast, according
Carreras et al. [78] the amount of PD-1 positive T cells is; a
high content is in a multivariate analysis does predict a
favorable outcome. It is a pity that in this series now known
prognostic factors like intrafollicular growth fraction and
vessel density (Koster et al. [79, 80], 2x) were not taken
along.
FoxP1 expression was studied in gastric extranodal MZL
by Han et al. [81]. About half the cases had nuclear
expression, which was correlated with shorter survival. It is
remarkable that in these patients surgery was often the
primary treatment, and the t (11; 18) status and HP
eradication data were not given. Sumida et al. [82] looked
into that specifically by analyzing HP-eradication success
in t (11; 18) positive cases; as expected, none of these
responded, nor did any f the HP negative cases. In
HP-positive, t (11; 18) positive responders’ serum titers of
antibodies against HP and the CagA protein were higher
than in nonresponders.
Several studies reported on prognostic factors in DLBL,
most of them took the activated-B and germinal center type
into account, although most study use the poor correlating
immunohistochemical profile for that. The 92 patients of
Ilic et al. [83] with immunohistochemically determined
GCB-type DLBCL did not have an improved prognosis,
irrespective of whether they had received rituximab or not.
According to Morito et al. [84], low serum soluble
interleukin-2 receptor levels and germinal center B cell-
like cases in 80 patients treated with rituximab were
predicting favorable outcome, but the results correlate
strongly with the IPI. Although these two markers may
substitute the IPI according to the authors, it seems to me
that the IPI is so well-established and easy to use, that this
will not happen.
Johnson et al. [85] report on 54 lymphomas with bcl2
and MYC translocations. These cases were classified as B
cell lymphoma unclassifiable with features intermediate
between Burkitt lymphoma and diffuse large B cell
lymphoma (DLBCL) [36], DLBCL [17] or follicular
lymphoma [1]. Non-immunoglobulin gene/MYC
(non-IG/MYC) translocations occurred in 24 of 54(44%)
and were highly associated with DLBCL morphology
(p<0.0001). A non-IG/MYC translocation partner, absent
BCL2 protein expression and treatment with rituximab-
based chemotherapy were associated with a more
favorable outcome but a low IPI score and DLBCL
morphology were independent predictors of OS.
An interesting study was reported by Balague et al. [86],
who analyzed the expression of activated X box-binding
protein 1 (Xbp-1) in reactive lymphoid tissues, 411
lymphomas and plasma-cell neoplasms, and 24 B cell
lines. Xbp-1 is a transcription factor that is required for the
terminal differentiation of B lymphocytes into plasma cells.
The Xbp-1 gene is activated in response to endoplasmic
reticulum stress signals, which generate a 50-kDa nuclear
protein that acts as a potent transactivator and regulates the
expression of genes related to the unfolded protein
response. Activated Xbp-1 is essential for cell survival in
plasma-cell tumors. None of the low-grade lymphomas
showed evidence of Xbp-1 activation; however, Xbp-1
activation was found in 28% of diffuse large B cell
lymphomas, independent of germinal or postgerminal
center phenotype, as well as in 48% of plasmablastic
lymphomas and 69% of plasma-cell neoplasms. Diffuse
large B cell lymphomas with nuclear Xbp-1 expression had
a significantly worse response to therapy and shorter
overall survival compared with negative tumors.
In 20 primary cutaneous follicle center cell lympho-
mas, Soltani-Arabshahi et al. [87] found that high RNA
expression levels of bcl-xL were related to low numbers of
apoptotic cells and indicated poor survival, whereas bcl-2
levels were not.
In 44 patients with nodal DLBL, Lee at al describe that
out of a series of eight genes studies, MGMT and p57
methylation correlated with better prognosis, dependent on
risk status. According to Curry et al. [88], based on 68
cases, c-Rel expression (65%) indicates better survival, but
only in the germinal center B subgroup. Kim et al. [89]
found the sonic hedgehog signaling proteins are more
prevalent in DLBL and patients with high expression of
ABCG2 have short survival (67 cases).
In a series of 30 PTCL, Briones et al. [90] investigated
the role of bcl10 and show that Bcl-10 is expressed in two-
thirds of the PTCLs, correlates with the expression of
upstream proteins PKC theta and Pp65(Ser536) and is
associated with better survival.
The amount of information on regulatory T cells (Treg)
is increasing fast, even though debate on their precise
phenotype in humans is ongoing. Using only FOXP3 as
marker for these cells, Kim et al. [91] show that in 64 cases
of extranodal NK/TCL high numbers of Treg are associated
with better survival, and that this is an independent
prognostic marker.
A few studies deal with prognostic markers for cutane-
ous TCL. In the erythrodermic group (124 cases, Vidulich
et al. [92]), serum LDH and age were the strongest
predictive factors for overall survival. ALCL (48 cases;
Woo et al. [93]) run an aggressive course in patients
presenting with extensive limb disease. In MF (70 cases;
Chandra et al. [94]), clusterin expression was in about half
of the patients, and especially in those with many large
atypical cells and high stage.
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Although it is well-known that bone marrow involvement is
rare in cutaneous lymphomas, and according to the WHO
classification in fact excludes the diagnosis of primary
cB-NHL, it is not clear whether all patients with cB-NHL
need to undergo a bone marrow biopsy. Based on a series of
57 patients, with only three positive marrows, Quereux et al.
[95] conclude that this investigation is not indispensible.
Most pathologists now perform routine immunohisto-
chemistry to detect limited involvement of the bone marrow
in staging biopsies. According to Baiyee et al. [96]., based
on 113 cases of DLBL, CD20 staining does not enhance
sensitivity, even not in histologically discordant cases,
which were about 40% of their 10% positive cases.
Ilgenfritz et al. [97] investigated the value of molecular
analysis for staging of the bone marrow in comparison with
routine methods. They conclude on data from 60 patients
that IGH PCR alone is not good enough for bone marrow
assessment, especially in FL. On the other hand, the PCR
study for BCL2 is more sensitive than morphology, without
any false negative results in this series, suggesting that
BCL2-MBR PCR can be used as an alternative and more
sensitive examination for disease evaluation, providing that
there is careful analysis of data, adequate knowledge of
PCR pitfalls and absence of other hematological disorders.
These latter remarks are quite important and preclude the
use in routine practice.
Ancillary techniques
Detection of leptomeningeal disease may influence treat-
ment of patients with aggressive B-NHL. Quijano et al. [98]
used advanced flow cytometrical (FCM) approaches and
found that 27 (22%) of 123 patients showed infiltration by
FCM, while conventional cytology (CC) was positive in
only seven patients (6%), with three other cases being
suspicious (2%). CC+/FCM+samples typically had more
than 20% neoplastic B cells and/or>or=one neoplastic B
cell/microL, while FCM+/CC- samples showed lower
levels of infiltration. Interestingly, in Burkitt lymphoma,
presence of CNS disease by FCM could be predicted with a
high specificity when increased serum beta2-microglobulin
and neurological symptoms coexisted, while peripheral
blood involvement was the only independent parameter
associated with CNS disease in diffuse large B cell
lymphoma, with low predictive value. A similar study, but
on a variety of lymphoma types and in only 32 cases by Wu
et al. [99] came to the same conclusion.
Fine needle aspirations are more and more done, also to
diagnose and classify lymphomas. Although HL is regarded
as a disease that can be reliably diagnosed on cytological
specimens, Das et al. [100] show that in about 25% of HL
diagnosis on cytology, the histological diagnosis was
different. When flow cytometry is added (252 cases of
NHL, Demurtas et al. [101]) diagnostic sensitivity and
specificity of the combination cytomorphology/FC were
97% and 94%, respectively. This therefore, might reduce
the number of invasive lymph node resections, especially
from difficult to reach sites.
Fromm et al. [102] looked into the reliability of flow
cytometry for the diagnosis of HL in lymph nodes. Of the
53 morphologically defined CHL cases identified, the FC
assay diagnostic sensitivity and specificity were 88.7% and
100%, respectively. With the current availability of eight
(or more) color clinical flow cytometers, this assay can now
be applied to routinely immunophenotype and confirm a
diagnosis of CHL or as an adjunct to immunohistochemical
analysis. However, this study does also show that there is
no added value above standard practice.
Intraocular lymphoma is very difficult to diagnose due to
the limited amount of cells that can be obtained. Sugita et
al. [103] show that using clonality testing and cytokine
profiling (IL6 and IL10) is very usefull to come to a reliable
diagnosis (22 patients). A completely different and new
approach was taken by Pantanelli et al. [104], who used
autofluorescence of cells in preclinical models and were
able to separate B- from T cells. Since the main differential
diagnosis from a B cell lymphoma in the uvea is uveitis,
and thus a T cell infiltrate, this approach is promising.
Clonality testing has become routine practice in most
laboratories for hematopathology. There are several well-
known pitfalls. Fan et al. [105] studied liver biopsies
from 40 hepatitis C virus infected patients and 800
controls. In the hepatitis group, light chain restriction
was present in four (10%) and three (0.4%) in the controls.
In five of these seven, a clonal IgH rearrangement was
found, and two of these five patients proved to have a B
cell lymphoma. So clonality does not always indicate
malignancy and light chain restriction not always clon-
ality. It is well-known that HL is a B cell lymphoma, and
with the new Biomed approach for clonality testing, that
includes detection of incomplete rearrangements, it could
be expected that HL samples will give clonal results.
Hebeda et al. [106] show that out of 24 cHL samples, 19
(79%) proved to be clonal using standard clonality testing
with the Biomed primers, i.e., without enrichment by
dissection of the tumor cells.
Several proteomic approaches are being tried for
classification of lymphomas, as discussed in an earlier
review. Now, Miquet et al. [107] did a mass spectrometry of
plasma membrane microparticles on 158 patients with
chronic B cell proliferation and 30 controls. This resulted
in the confirmation of CD 148 as a good marker for MCL,
specificity of 91%, but sensitivity of 78%.
J Hematopathol (2009) 2:171–183 179Romesser et al. [108] build further on their gene
expression array work in a mouse model, where they were
able to translate the results in protein patterns and conclude
that results support the central hypothesis that clusters of
proteins of known function represent a panel of expression
markers uniquely associated with malignancy and not
normal proliferation. A fact that conclusion was already
supported by the work of Jansen et al. [109], although their
approach made identification of individual proteins not
possible.
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